Central Vein Sign in Pediatric Multiple Sclerosis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Copyright © 2023 Elsevier Inc. All rights reserved..
BACKGROUND: The central vein sign (CVS) on brain magnetic resonance imaging (MRI) is a promising diagnostic marker for distinguishing adult multiple sclerosis (MS) from other demyelinating conditions, but its prevalence is not well-established in pediatric-onset multiple sclerosis (POMS) versus myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD can mimic MS radiologically. This study seeks to determine the utility of CVS, together with other radiological findings, in distinguishing POMS from MOGAD in children.
METHODS: Children with POMS or MOGAD were identified in a pediatric demyelinating database. Two reviewers, blinded to diagnosis, fused fluid-attenuated inversion recovery sequences and susceptibility-weighted imaging from clinical imaging to identify CVS. Agreement in CVS number was reported using intraclass correlation coefficients (ICC). We performed topographic analyses as well as characterization of the clinical information and lesions on brain, spinal cord, and orbital MRI when available.
RESULTS: Twenty children, 10 with POMS and 10 with MOGAD, were assessed. The median lesion percentage of CVS was higher in POMS versus MOGAD for both raters (rater 1: 80% vs 9.8%; rater 2: 22.7% vs 7.5%). Inter-rater reliability for identifying total white matter lesions was strong (ICC 0.94 [95% confidence interval [CI] 0.84, 0.97]); however, it was poor for detecting CVS lesions (ICC -0.17 [95% CI: -0.37, 0.58]).
CONCLUSION: The CVS can be a useful diagnostic tool for differentiating POMS from MOGAD. However, advanced clinical imaging tools that can better detect CVS are needed to increase inter-rater reliability before clinical application.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:146 |
|---|---|
| Enthalten in: |
Pediatric neurology - 146(2023) vom: 30. Sept., Seite 21-25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Harrison, Kimystian L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 07.08.2023 Date Revised 07.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pediatrneurol.2023.05.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35907572X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35907572X | ||
| 003 | DE-627 | ||
| 005 | 20231226080111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pediatrneurol.2023.05.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM35907572X | ||
| 035 | |a (NLM)37406422 | ||
| 035 | |a (PII)S0887-8994(23)00158-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Harrison, Kimystian L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Central Vein Sign in Pediatric Multiple Sclerosis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.08.2023 | ||
| 500 | |a Date Revised 07.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The central vein sign (CVS) on brain magnetic resonance imaging (MRI) is a promising diagnostic marker for distinguishing adult multiple sclerosis (MS) from other demyelinating conditions, but its prevalence is not well-established in pediatric-onset multiple sclerosis (POMS) versus myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD can mimic MS radiologically. This study seeks to determine the utility of CVS, together with other radiological findings, in distinguishing POMS from MOGAD in children | ||
| 520 | |a METHODS: Children with POMS or MOGAD were identified in a pediatric demyelinating database. Two reviewers, blinded to diagnosis, fused fluid-attenuated inversion recovery sequences and susceptibility-weighted imaging from clinical imaging to identify CVS. Agreement in CVS number was reported using intraclass correlation coefficients (ICC). We performed topographic analyses as well as characterization of the clinical information and lesions on brain, spinal cord, and orbital MRI when available | ||
| 520 | |a RESULTS: Twenty children, 10 with POMS and 10 with MOGAD, were assessed. The median lesion percentage of CVS was higher in POMS versus MOGAD for both raters (rater 1: 80% vs 9.8%; rater 2: 22.7% vs 7.5%). Inter-rater reliability for identifying total white matter lesions was strong (ICC 0.94 [95% confidence interval [CI] 0.84, 0.97]); however, it was poor for detecting CVS lesions (ICC -0.17 [95% CI: -0.37, 0.58]) | ||
| 520 | |a CONCLUSION: The CVS can be a useful diagnostic tool for differentiating POMS from MOGAD. However, advanced clinical imaging tools that can better detect CVS are needed to increase inter-rater reliability before clinical application | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Central vein | |
| 650 | 4 | |a MOG | |
| 650 | 4 | |a MS | |
| 650 | 4 | |a Myelin oligodendrocyte glycoprotein | |
| 650 | 4 | |a Pediatric multiple sclerosis | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Gaudioso, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Levasseur, Victoria A |e verfasserin |4 aut | |
| 700 | 1 | |a Dunham, S Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Schanzer, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Keuchel, Connor |e verfasserin |4 aut | |
| 700 | 1 | |a Salter, Amber |e verfasserin |4 aut | |
| 700 | 1 | |a Goyal, Manu S |e verfasserin |4 aut | |
| 700 | 1 | |a Mar, Soe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric neurology |d 1993 |g 146(2023) vom: 30. Sept., Seite 21-25 |w (DE-627)NLM012947210 |x 1873-5150 |7 nnns |
| 773 | 1 | 8 | |g volume:146 |g year:2023 |g day:30 |g month:09 |g pages:21-25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pediatrneurol.2023.05.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 146 |j 2023 |b 30 |c 09 |h 21-25 | ||